255 related articles for article (PubMed ID: 23610140)
1. Local administration of TLR ligands rescues the function of tumor-infiltrating CD8 T cells and enhances the antitumor effect of lentivector immunization.
Xiao H; Peng Y; Hong Y; Huang L; Guo ZS; Bartlett DL; Fu N; Munn DH; Mellor A; He Y
J Immunol; 2013 Jun; 190(11):5866-73. PubMed ID: 23610140
[TBL] [Abstract][Full Text] [Related]
2. Blockade of programmed death-1 pathway rescues the effector function of tumor-infiltrating T cells and enhances the antitumor efficacy of lentivector immunization.
Zhou Q; Xiao H; Liu Y; Peng Y; Hong Y; Yagita H; Chandler P; Munn DH; Mellor A; Fu N; He Y
J Immunol; 2010 Nov; 185(9):5082-92. PubMed ID: 20926790
[TBL] [Abstract][Full Text] [Related]
3. Lentivector immunization stimulates potent CD8 T cell responses against melanoma self-antigen tyrosinase-related protein 1 and generates antitumor immunity in mice.
Liu Y; Peng Y; Mi M; Guevara-Patino J; Munn DH; Fu N; He Y
J Immunol; 2009 May; 182(10):5960-9. PubMed ID: 19414747
[TBL] [Abstract][Full Text] [Related]
4. Intratumoral CD8
Horton BL; Williams JB; Cabanov A; Spranger S; Gajewski TF
Cancer Immunol Res; 2018 Jan; 6(1):14-24. PubMed ID: 29097422
[TBL] [Abstract][Full Text] [Related]
5. The Inhibitory Signaling Receptor Protocadherin-18 Regulates Tumor-Infiltrating CD8
Frey AB
Cancer Immunol Res; 2017 Oct; 5(10):920-928. PubMed ID: 28874354
[TBL] [Abstract][Full Text] [Related]
6. Effector, Memory, and Dysfunctional CD8(+) T Cell Fates in the Antitumor Immune Response.
Reiser J; Banerjee A
J Immunol Res; 2016; 2016():8941260. PubMed ID: 27314056
[TBL] [Abstract][Full Text] [Related]
7. Autocrine Complement Inhibits IL10-Dependent T-cell-Mediated Antitumor Immunity to Promote Tumor Progression.
Wang Y; Sun SN; Liu Q; Yu YY; Guo J; Wang K; Xing BC; Zheng QF; Campa MJ; Patz EF; Li SY; He YW
Cancer Discov; 2016 Sep; 6(9):1022-35. PubMed ID: 27297552
[TBL] [Abstract][Full Text] [Related]
8. Reversing tumor immune suppression with intratumoral IL-12: activation of tumor-associated T effector/memory cells, induction of T suppressor apoptosis, and infiltration of CD8+ T effectors.
Kilinc MO; Aulakh KS; Nair RE; Jones SA; Alard P; Kosiewicz MM; Egilmez NK
J Immunol; 2006 Nov; 177(10):6962-73. PubMed ID: 17082611
[TBL] [Abstract][Full Text] [Related]
9. Immunoglobulin Fc fragment tagging allows strong activation of endogenous CD4 T cells to reshape the tumor milieu and enhance the antitumor effect of lentivector immunization.
Hong Y; Peng Y; Xiao H; Mi M; Munn D; He Y
J Immunol; 2012 May; 188(10):4819-27. PubMed ID: 22504640
[TBL] [Abstract][Full Text] [Related]
10. Targeting Tumors with IL-10 Prevents Dendritic Cell-Mediated CD8
Qiao J; Liu Z; Dong C; Luan Y; Zhang A; Moore C; Fu K; Peng J; Wang Y; Ren Z; Han C; Xu T; Fu YX
Cancer Cell; 2019 Jun; 35(6):901-915.e4. PubMed ID: 31185213
[TBL] [Abstract][Full Text] [Related]
11. Adenosine mediates functional and metabolic suppression of peripheral and tumor-infiltrating CD8
Mastelic-Gavillet B; Navarro Rodrigo B; Décombaz L; Wang H; Ercolano G; Ahmed R; Lozano LE; Ianaro A; Derré L; Valerio M; Tawadros T; Jichlinski P; Nguyen-Ngoc T; Speiser DE; Verdeil G; Gestermann N; Dormond O; Kandalaft L; Coukos G; Jandus C; Ménétrier-Caux C; Caux C; Ho PC; Romero P; Harari A; Vigano S
J Immunother Cancer; 2019 Oct; 7(1):257. PubMed ID: 31601268
[TBL] [Abstract][Full Text] [Related]
12. Increased numbers of monocyte-derived dendritic cells during successful tumor immunotherapy with immune-activating agents.
Kuhn S; Hyde EJ; Yang J; Rich FJ; Harper JL; Kirman JR; Ronchese F
J Immunol; 2013 Aug; 191(4):1984-92. PubMed ID: 23858033
[TBL] [Abstract][Full Text] [Related]
13. TGFβ1-Mediated SMAD3 Enhances PD-1 Expression on Antigen-Specific T Cells in Cancer.
Park BV; Freeman ZT; Ghasemzadeh A; Chattergoon MA; Rutebemberwa A; Steigner J; Winter ME; Huynh TV; Sebald SM; Lee SJ; Pan F; Pardoll DM; Cox AL
Cancer Discov; 2016 Dec; 6(12):1366-1381. PubMed ID: 27683557
[TBL] [Abstract][Full Text] [Related]
14. PGE
Lacher SB; Dörr J; de Almeida GP; Hönninger J; Bayerl F; Hirschberger A; Pedde AM; Meiser P; Ramsauer L; Rudolph TJ; Spranger N; Morotti M; Grimm AJ; Jarosch S; Oner A; Gregor L; Lesch S; Michaelides S; Fertig L; Briukhovetska D; Majed L; Stock S; Busch DH; Buchholz VR; Knolle PA; Zehn D; Dangaj Laniti D; Kobold S; Böttcher JP
Nature; 2024 May; 629(8011):417-425. PubMed ID: 38658748
[TBL] [Abstract][Full Text] [Related]
15. Functional Heterogeneity of CD4
Oja AE; Piet B; van der Zwan D; Blaauwgeers H; Mensink M; de Kivit S; Borst J; Nolte MA; van Lier RAW; Stark R; Hombrink P
Front Immunol; 2018; 9():2654. PubMed ID: 30505306
[TBL] [Abstract][Full Text] [Related]
16. Targeting PD-1 and Tim-3 Pathways to Reverse CD8 T-Cell Exhaustion and Enhance Ex Vivo T-Cell Responses to Autologous Dendritic/Tumor Vaccines.
Liu J; Zhang S; Hu Y; Yang Z; Li J; Liu X; Deng L; Wang Y; Zhang X; Jiang T; Lu X
J Immunother; 2016 May; 39(4):171-80. PubMed ID: 27070448
[TBL] [Abstract][Full Text] [Related]
17. Cooperation between Constitutive and Inducible Chemokines Enables T Cell Engraftment and Immune Attack in Solid Tumors.
Dangaj D; Bruand M; Grimm AJ; Ronet C; Barras D; Duttagupta PA; Lanitis E; Duraiswamy J; Tanyi JL; Benencia F; Conejo-Garcia J; Ramay HR; Montone KT; Powell DJ; Gimotty PA; Facciabene A; Jackson DG; Weber JS; Rodig SJ; Hodi SF; Kandalaft LE; Irving M; Zhang L; Foukas P; Rusakiewicz S; Delorenzi M; Coukos G
Cancer Cell; 2019 Jun; 35(6):885-900.e10. PubMed ID: 31185212
[TBL] [Abstract][Full Text] [Related]
18. The Emerging Role of CD8
Corgnac S; Boutet M; Kfoury M; Naltet C; Mami-Chouaib F
Front Immunol; 2018; 9():1904. PubMed ID: 30158938
[TBL] [Abstract][Full Text] [Related]
19. Intravenous injection of MVA virus targets CD8+ lymphocytes to tumors to control tumor growth upon combinatorial treatment with a TLR9 agonist.
Fend L; Gatard-Scheikl T; Kintz J; Gantzer M; Schaedler E; Rittner K; Cochin S; Fournel S; Préville X
Cancer Immunol Res; 2014 Dec; 2(12):1163-74. PubMed ID: 25168392
[TBL] [Abstract][Full Text] [Related]
20. High DGK-α and disabled MAPK pathways cause dysfunction of human tumor-infiltrating CD8+ T cells that is reversible by pharmacologic intervention.
Prinz PU; Mendler AN; Masouris I; Durner L; Oberneder R; Noessner E
J Immunol; 2012 Jun; 188(12):5990-6000. PubMed ID: 22573804
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
